Nexplanon (Etonogestrel)

Etonogestrel released from the implant binds to progesterone receptors, suppressing the luteinizing hormone surge and preventing ovulation. It also thickens cervical mucus and alters the endometrium, creating multiple barriers to fertilization and implantation.

The Nexplanon implant contains a fixed 68 mg dose of etonogestrel. The prescriber determines suitability and inserts the single‑use device; no additional dosing regimen is required by the patient.

Nexplanon is contraindicated in pregnancy (pregnancy category X) and should be removed if pregnancy occurs. It is generally considered safe for breastfeeding women, but clinicians should discuss individual risks and benefits with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Compared with oral contraceptives, Nexplanon offers a once‑in‑a‑lifetime insertion lasting up to three years, eliminating daily adherence. Unlike intrauterine devices, it does not require uterine placement and can be removed at any time without affecting future fertility.

Nexplanon should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the implant from moisture and direct sunlight until it is inserted by a qualified healthcare professional.

A qualified clinician inserts the 68 mg etonogestrel implant subdermally into the inner side of the upper arm using a sterile applicator. The procedure takes only a few minutes and is performed in an outpatient setting.

Serious risks include deep vein thrombosis, pulmonary embolism, severe allergic reactions, infection at the insertion site, and rare cases of ectopic pregnancy if contraceptive failure occurs. Patients should seek immediate medical attention if they experience symptoms such as leg swelling, chest pain, or severe skin reactions.

Women with a history of thromboembolic disorders, active breast cancer, severe liver disease, or known hypersensitivity to etonogestrel or any component of the implant should not use Nexplanon. It is also contraindicated during pregnancy.